scispace - formally typeset
T

Takashi Koyano

Researcher at Chiba University

Publications -  94
Citations -  1904

Takashi Koyano is an academic researcher from Chiba University. The author has contributed to research in topics: Cell culture & Wnt signaling pathway. The author has an hindex of 25, co-authored 94 publications receiving 1759 citations. Previous affiliations of Takashi Koyano include Kyoto Prefectural University of Medicine & Keio University.

Papers
More filters
Journal ArticleDOI

Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription.

TL;DR: The results strongly suggest that the cytotoxicity of the compounds to PANC1 cells correlates with their inhibition of GLI‐mediated transcription, and that these compounds were cytotoxic to P ANC1 pancreatic cancer cells, which express Hh/GLI components.
Journal ArticleDOI

Induction of normal phenotypes in ras-transformed cells by damnacanthal from Morinda citrifolia

TL;DR: The compound isolated from the chloroform extract of the root of Morinda citrifolia induced normal morphology and cytoskeletal structure in K-rasts-NRK cells at the permissive temperature, without changing the amount and localization of Ras.
Journal ArticleDOI

Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.

TL;DR: Aglaiastatin reduced the amount of Ras, possibly by inhibiting its de novo synthesis, and was slightly more potent than 1 and 2 in inhibiting cell growth.
Journal ArticleDOI

Leishmanicidal alkaloids from Kopsia griffithii

TL;DR: Thirteen alkaloids were isolated from the stem-bark extract of Kopsia griffithii, of which three were new, and Harmane, pleiocarpine and buchtienine showed antileishmanial activity.
Journal ArticleDOI

Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells.

TL;DR: A dihydroflavonol that was extracted from Blumea balsamifera (BB-1) exhibited the most striking synergism with TRAIL, suggesting that combined treatment with BB-1 and TRAIL may be a new strategy for cancer therapy.